| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9005678 | Clinical Therapeutics | 2005 | 12 Pages |
Abstract
The present review of the available Phase III clinical trial suggests that efalizumab is not associated with an increased risk for infection in patients receiving initial or long-term (27-month) treatment for moderate to severe chronic plaque psoriasis.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
MD, FRCPC Langley, MD Carey, MD Rafal, MD, PhD Tyring, MD Caro, ScD Wang, MSc Wetherill, MD Gordon,